NYSE · GEHC
Healthcare · Medical - Healthcare Information Services
$76.42
Up+$0.15 (+0.20%)
Updated Oct 30, 2026, 11:50 PM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · GEHC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
GEHC closed at $76.42 after 21 trading sessions, up 19.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $76.20 | $77.33 | $75.40 | $76.42 | 4.65M |
| Oct 28, 2026 | $76.00 | $77.88 | $74.64 | $75.82 | 9.57M |
| Oct 27, 2026 | $71.73 | $71.8025 | $70.17 | $71.11 | 5.06M |
| Oct 26, 2026 | $71.19 | $72.30 | $71.00 | $71.98 | 2.87M |
| Oct 23, 2026 | $70.74 | $71.86 | $70.095 | $71.45 | 2.98M |
| Oct 22, 2026 | $69.325 | $71.70 | $69.31 | $71.42 | 3.13M |
| Oct 21, 2026 | $69.02 | $70.26 | $68.70 | $69.01 | 2.18M |
| Oct 20, 2026 | $70.25 | $71.02 | $69.63 | $70.23 | 2.26M |
| Oct 19, 2026 | $69.29 | $70.08 | $69.06 | $69.76 | 2.28M |
| Oct 16, 2026 | $71.10 | $71.32 | $69.45 | $69.57 | 3.12M |
| Oct 15, 2026 | $69.80 | $70.99 | $69.50 | $70.35 | 3.75M |
| Oct 14, 2026 | $68.92 | $69.51 | $67.66 | $68.47 | 5.03M |
| Oct 13, 2026 | $67.74 | $69.36 | $67.36 | $68.79 | 3.44M |
| Oct 12, 2026 | $66.015 | $68.34 | $65.74 | $67.74 | 3.75M |
| Oct 9, 2026 | $64.34 | $65.78 | $64.29 | $65.74 | 2.86M |
| Oct 8, 2026 | $64.28 | $64.505 | $63.315 | $64.22 | 4.95M |
| Oct 7, 2026 | $64.93 | $65.44 | $64.03 | $64.67 | 4.07M |
| Oct 6, 2026 | $66.04 | $66.55 | $64.6705 | $64.77 | 3.55M |
| Oct 5, 2026 | $63.62 | $65.865 | $63.37 | $65.74 | 4.3M |
| Oct 2, 2026 | $64.73 | $64.985 | $63.955 | $64.29 | 3.24M |
| Oct 1, 2026 | $65.37 | $65.545 | $63.8601 | $63.98 | 3.31M |
The latest Smart Investors Daily articles mentioning GEHC.
Company
Market Activity
Research & News
GEHC research
Company profile and research snapshot.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | JP Morgan | Neutral | — |
| Oct 29, 2026 | Barclays | Overweight | — |
| Oct 29, 2026 | RBC Capital | Outperform | — |
| Oct 29, 2026 | Citigroup | Neutral | — |
| Oct 28, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Mar 27, 2026
GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Mar 27, 2026
These companies are ready to deliver on the AI-fueled hype.
Yahoo · Mar 26, 2026
CHICAGO, March 26, 2026--GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI
Benzinga · Mar 26, 2026
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GEHC.
